These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22224491)

  • 1. Skin fragility and blistering secondary to imatinib.
    Reddy H; Horne HL; Maung Z
    Clin Exp Dermatol; 2012 Jul; 37(5):572-3. PubMed ID: 22224491
    [No Abstract]   [Full Text] [Related]  

  • 2. Skin fragility and blistering with imatinib mesylate.
    Verma SM; Murphy G
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):496-8. PubMed ID: 19925597
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
    Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
    Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
    [No Abstract]   [Full Text] [Related]  

  • 4. Follicular mucinosis associated with imatinib (STI571).
    Yanagi T; Sawamura D; Shimizu H
    Br J Dermatol; 2004 Dec; 151(6):1276-8. PubMed ID: 15606531
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib mesylate induced erythroderma.
    Sanghavi SA; Dongre AM; Khopkar US
    Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral lichenoid eruption associated with imatinib treatment.
    Gómez Fernández C; Sendagorta Cudós E; Casado Verrier B; Feito Rodríguez M; Suárez Aguado J; Vidaurrázaga Díaz de Arcaya C
    Eur J Dermatol; 2010; 20(1):127-8. PubMed ID: 19825526
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
    Vano-Galvan S; Fernandez-Guarino M; Henriquez-Santana A; De Las Heras E; Calbacho M; Jaen P
    Eur J Dermatol; 2007; 17(6):538-9. PubMed ID: 17951138
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib: a designer drug, another cutaneous complication.
    Dickens E; Lewis F; Bienz N
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
    Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
    Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
    [No Abstract]   [Full Text] [Related]  

  • 11. Pseudoporphyria induced by imatinib mesylate.
    Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
    Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
    [No Abstract]   [Full Text] [Related]  

  • 12. Follicular acneiform eruption induced by imatinib.
    Martín JM; Jordá E; Monteagudo C; Alonso V; García L; Villalón G
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1368-70. PubMed ID: 17062082
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous reactions to STI571.
    Brouard M; Saurat JH
    N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
    [No Abstract]   [Full Text] [Related]  

  • 14. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 15. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
    Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
    Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 17. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
    Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
    Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.